Cancer Discovery：细胞对CRISPR的应答不容忽视

2016-06-10 叶子生物通

这两年几乎人人都在谈论CRISPR基因组编辑，那么细胞对这个系统的闯入作何感想呢？Cancer Discovery杂志最近发表的一项研究指出，细胞会对CRISPR-Cas9产生一种不容忽视的应答。细菌一直在与病毒或入侵核酸进行斗争，为此它们演化出了多种防御机制，CRISPR-Cas适应性免疫系统就是其中之一。规律成簇的间隔短回文重复CRISPR与内切酶Cas9的组合，可以在引导RNA的指引

这两年几乎人人都在谈论CRISPR基因组编辑，那么细胞对这个系统的闯入作何感想呢？Cancer Discovery杂志最近发表的一项研究指出，细胞会对CRISPR-Cas9产生一种不容忽视的应答。

细菌一直在与病毒或入侵核酸进行斗争，为此它们演化出了多种防御机制，CRISPR-Cas适应性免疫系统就是其中之一。规律成簇的间隔短回文重复CRISPR与内切酶Cas9的组合，可以在引导RNA的指引下，靶标并切割入侵者的遗传物质。这种特性使CRISPR系统成为了基因组编辑和基因功能研究的实用工具。

CRISPR-Cas9能够很方便的在哺乳动物细胞中进行体细胞遗传筛选。但哈佛大学Dana-Farber癌症研究所的科学家们在实践中发现，CRISPR-Cas9靶标会使细胞产生一种不依赖基因的应答。而这种应答会干扰人们对CRISPR筛选数据的解读。

为了鉴定增殖的必需基因，研究人员用CRISPR-Cas9在33个癌细胞系中进行了全基因组的功能缺失筛选。他们发现，基因组编辑之后的基因拷贝数增加和细胞活力下降有很强的关联。

在拷贝数增加的区域中，CRISPR-Cas9靶标会诱导G2细胞周期停滞，由此显著减少癌细胞的增殖。这项研究表明，被CRISPR-Cas9靶标的基因组引起了不依赖基因的抗增殖细胞应答。理解这种影响对于正确解读CRISPR-Cas9筛选数据非常重要。

基因筛选是经典的生物学研究方法，常用于鉴定在生物学过程中起作用的基因。十多年来RNAi一直是这一领域的王者，然而新兴技术的涌现（尤其是CRISPR技术）正在逐渐瓦解RNAi的统治地位。那么，在RNAi和CRISPR筛选之间我们究竟应该如何抉择呢？斯坦福大学的研究人员对这两种技术进行了全面比较，并将研究结果发表在Nature Biotechnology杂志上。

原始出处

Andrew J. Aguirre1, Robin M. Meyers2, Barbara A. Weir1, Francisca Vazquez1.et.al.Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting.Cancer Discovery.2016

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2012098, encodeId=6f34201209813, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 29 08:59:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783685, encodeId=f7e41e83685da, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Oct 07 07:59:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275887, encodeId=ab9812e5887e6, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sun Jun 12 02:59:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587797, encodeId=4699158e797f2, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Sun Jun 12 02:59:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89314, encodeId=0e7b89314c9, content=肿瘤免疫研究大有发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=044375165, createdName=sygao2002, createdTime=Sat Jun 11 07:23:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89276, encodeId=ddd1892e67b, content=值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Fri Jun 10 22:59:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89275, encodeId=ab13892e5f6, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Fri Jun 10 22:58:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
2017-01-29 cmj8wellington

#Dis#

36 0
[GetPortalCommentsPageByObjectIdResponse(id=2012098, encodeId=6f34201209813, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 29 08:59:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783685, encodeId=f7e41e83685da, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Oct 07 07:59:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275887, encodeId=ab9812e5887e6, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sun Jun 12 02:59:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587797, encodeId=4699158e797f2, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Sun Jun 12 02:59:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89314, encodeId=0e7b89314c9, content=肿瘤免疫研究大有发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=044375165, createdName=sygao2002, createdTime=Sat Jun 11 07:23:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89276, encodeId=ddd1892e67b, content=值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Fri Jun 10 22:59:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89275, encodeId=ab13892e5f6, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Fri Jun 10 22:58:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
2016-10-07 yahu

#cover#

33 0
[GetPortalCommentsPageByObjectIdResponse(id=2012098, encodeId=6f34201209813, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 29 08:59:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783685, encodeId=f7e41e83685da, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Oct 07 07:59:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275887, encodeId=ab9812e5887e6, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sun Jun 12 02:59:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587797, encodeId=4699158e797f2, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Sun Jun 12 02:59:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89314, encodeId=0e7b89314c9, content=肿瘤免疫研究大有发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=044375165, createdName=sygao2002, createdTime=Sat Jun 11 07:23:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89276, encodeId=ddd1892e67b, content=值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Fri Jun 10 22:59:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89275, encodeId=ab13892e5f6, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Fri Jun 10 22:58:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
2016-06-12 yuandd

#CRISPR#

29 0
[GetPortalCommentsPageByObjectIdResponse(id=2012098, encodeId=6f34201209813, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 29 08:59:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783685, encodeId=f7e41e83685da, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Oct 07 07:59:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275887, encodeId=ab9812e5887e6, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sun Jun 12 02:59:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587797, encodeId=4699158e797f2, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Sun Jun 12 02:59:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89314, encodeId=0e7b89314c9, content=肿瘤免疫研究大有发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=044375165, createdName=sygao2002, createdTime=Sat Jun 11 07:23:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89276, encodeId=ddd1892e67b, content=值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Fri Jun 10 22:59:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89275, encodeId=ab13892e5f6, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Fri Jun 10 22:58:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
2016-06-12 yankaienglish

#ISC#

40 0
[GetPortalCommentsPageByObjectIdResponse(id=2012098, encodeId=6f34201209813, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 29 08:59:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783685, encodeId=f7e41e83685da, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Oct 07 07:59:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275887, encodeId=ab9812e5887e6, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sun Jun 12 02:59:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587797, encodeId=4699158e797f2, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Sun Jun 12 02:59:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89314, encodeId=0e7b89314c9, content=肿瘤免疫研究大有发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=044375165, createdName=sygao2002, createdTime=Sat Jun 11 07:23:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89276, encodeId=ddd1892e67b, content=值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Fri Jun 10 22:59:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89275, encodeId=ab13892e5f6, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Fri Jun 10 22:58:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
2016-06-11 sygao2002

肿瘤免疫研究大有发展

112 0
[GetPortalCommentsPageByObjectIdResponse(id=2012098, encodeId=6f34201209813, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 29 08:59:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783685, encodeId=f7e41e83685da, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Oct 07 07:59:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275887, encodeId=ab9812e5887e6, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sun Jun 12 02:59:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587797, encodeId=4699158e797f2, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Sun Jun 12 02:59:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89314, encodeId=0e7b89314c9, content=肿瘤免疫研究大有发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=044375165, createdName=sygao2002, createdTime=Sat Jun 11 07:23:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89276, encodeId=ddd1892e67b, content=值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Fri Jun 10 22:59:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89275, encodeId=ab13892e5f6, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Fri Jun 10 22:58:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
2016-06-10 milkshark

值得研究

112 0
[GetPortalCommentsPageByObjectIdResponse(id=2012098, encodeId=6f34201209813, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 29 08:59:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783685, encodeId=f7e41e83685da, content=<a href='/topic/show?id=d195513038' target=_blank style='color:#2F92EE;'>#cover#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5130, encryptionId=d195513038, topicName=cover)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Fri Oct 07 07:59:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275887, encodeId=ab9812e5887e6, content=<a href='/topic/show?id=755d5211a0' target=_blank style='color:#2F92EE;'>#CRISPR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5211, encryptionId=755d5211a0, topicName=CRISPR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Sun Jun 12 02:59:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587797, encodeId=4699158e797f2, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Sun Jun 12 02:59:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89314, encodeId=0e7b89314c9, content=肿瘤免疫研究大有发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=044375165, createdName=sygao2002, createdTime=Sat Jun 11 07:23:00 CST 2016, time=2016-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89276, encodeId=ddd1892e67b, content=值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Fri Jun 10 22:59:00 CST 2016, time=2016-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89275, encodeId=ab13892e5f6, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Fri Jun 10 22:58:00 CST 2016, time=2016-06-10, status=1, ipAttribution=)]
2016-06-10 milkshark

的确这样

93 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

转化医学

Cancer Discovery：细胞对CRISPR的应答不容忽视

相关资讯

科室

工具

服务